Skip to main content

Table 9 Predictive risk of CCA recurrence in early stage patients using soluble CD44, CD44v6, CD44v8-10, and EpCAM

From: Overexpression of a panel of cancer stem cell markers enhances the predictive capability of the progression and recurrence in the early stage cholangiocarcinoma

Comparative predictionPost-operative recurrence
OR crudep (95% CI)OR adjustedp (95% CI)
CD44 ≥ 0.505 vs. < 0.5053.670.022 (1.207–11.183)3.620.031 (1.126–11.66)
CD44v6 ≥ 0.814 vs. < 0.8144.640.008 (1.503–14.346)4.980.009 (1.504–16.473)
CD44v8-10 ≥ 0.713 vs. < 0.7136.550.002 (2.029-21.116)5.920.004 (1.779-19.706)
EpCAM ≥ 0.814 vs. < 0.8146.910.001 (2.147–22.202)6.230.003 (1.867–20.793)
  1. CD44 cluster of differentiation 44, CD44v CD44 variant, EpCAM epithelial cell adhesion molecules, OR odds ratio, OR adjusted odds ratio adjusted for age and sex statistical analysis, 95% CI 95% confidence interval